Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of pramlintide as adjunctive therapy to insulin in patients with type 2 diabetes over 52 weeks. Pramlintide is a synthetic analog of amylin, a pancreatic hormone co-secreted with insulin that regulates postprandial glycemia.

Patients already on insulin with or without oral agents were randomized to receive pramlintide at doses of 30, 75, or 120 mcg subcutaneously three times daily before meals, or placebo. The primary endpoint was the change in HbA1c from baseline.

The results demonstrated that pramlintide at the 120 mcg dose produced:

• Sustained reduction in HbA1c over 52 weeks
• Associated weight loss, in contrast to the typical weight gain from insulin intensification
• Reduction in postprandial glycemic excursions
• No increase in severe hypoglycemia rate compared to placebo

The combination of glycemic improvement with weight loss is particularly significant, as intensification of insulin therapy typically results in weight gain. The mechanism of pramlintide involves slowing gastric emptying, suppression of postprandial glucagon secretion, and promotion of satiety. This study was fundamental for the FDA approval of pramlintide (Symlin) as an adjunct to insulin.